Back to results
US 11,644,467 B2Granted
Prediction of response to immune-modulatory therapies
AssigneeYale University
InventorsDavid L. Rimm, Kurt Schalper
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of treating cancer by immune checkpoint blockade, or selecting patients for treatment with immune checkpoint blockers, by detecting tumors with high levels of T-lymphocytes with low levels of activation and proliferation. In various embodiments the tissue sample may be from a conventional biopsy. In various embodiments the cancer may be non-small cell lung cancer.
Claims22
A method of treating cancer comprising:
- a) measuring a level of at least one marker for T-lymphocytes, a level of at least one marker for proliferation in the T-lymphocytes and a level of at least one marker for activation in the T-lymphocytes in a pre-treatment tumor tissue sample from a patient,
- b) comparing the level of the marker for T-lymphocytes, the level of the marker for activation and the level of the marker for proliferation to corresponding predetermined reference levels,
- c) treating the patient with at least one immune checkpoint blocker when the level of the marker for T-lymphocytes is above the corresponding reference level, when the level of the marker for activation is below the corresponding reference level and when the level of the marker for proliferation is below the corresponding reference level.
A method of selecting patients for treatment with immune checkpoint blockers comprising:
- a) measuring a level of at least one marker for T-lymphocytes, a level of at least one marker for proliferation in the T-lymphocytes and a level of at least one marker for activation in the T-lymphocytes in a pre-treatment tumor tissue sample from a patient,
- b) comparing the level of the marker for T-lymphocytes, the level of the marker for activation and the level of the marker for proliferation to corresponding predetermined reference levels,
- c) treating the patient with at least one immune checkpoint blocker when the level of the marker for T-lymphocytes is above the corresponding reference level, when the level of the marker for activation is below the corresponding reference level and when the level of the marker for proliferation is below the corresponding reference level.
Dependencies are inferred from the claim text.